The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
|Poll|January 11, 2017
A Distal Dermatitis
Author(s)Jonathan A. Schneider, DO
Can you identify this acral eruption of a week's duration on a 3-year-old boy?
Advertisement
A 3-year-old boy is seen for an acral rash of 7 days’ duration-an eruption of symmetric, flesh-colored monomorphous papules on arms, legs, buttocks, and face. Moderately enlarged, tender cervical lymph nodes are palpated.
What is the most likely diagnosis?
Advertisement
Related to this article
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5